Therapeutics Archives

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met major and all key secondary endpoints; favorable security and tolerability knowledge noticed Single dose of lonvo-z freed most sufferers from each assaults and ongoing remedy for six-month efficacy analysis interval, demonstrating its potential to be the primary and solely one-time HAE remedy Rolling biologics license utility (BLA)…

Eli Lilly’s .25B acquisition of Kelonia Therapeutics caps startup’s tortuous ride

Eli Lilly’s $3.25B acquisition of Kelonia Therapeutics caps startup’s tortuous ride

Suhas Bhokare4 weeks ago3 weeks ago02 mins

Eli Lilly is spending $3.25 billion to accumulate Kelonia Therapeutics, a small biotech firm growing cell therapies for most cancers and autoimmune ailments, the businesses introduced Monday. Lilly might pay extra if Kelonia achieves specified scientific, regulatory, and business milestones. The acquisition is a boon for the small startup, which has subsisted on $60 million…

Neurocrine to buy Soleno Therapeutics for .9 billion

Neurocrine to buy Soleno Therapeutics for $2.9 billion

Suhas Bhokare19 years ago1 month ago01 mins

April 6 (Reuters) – Neurocrine Biosciences will purchase uncommon illness drugmaker ‌Soleno Therapeutics for $2.9 billion in ‌money, the businesses stated on Monday, marking the neuroscience-focused drugmaker’s growth into metabolic problems. Neurocrine has provided $53 per Soleno share held, which represents a premium ‌of about ⁠34% to inventory’s final shut. Soleno shares, which had risen…